Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis

Abhiram Prasad, Julian P J Halcox, Myron A. Waclawiw, Arshed A. Quyyumi

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

OBJECTIVES: This study was performed to determine whether angiotensin type 1 (AT1) receptor inhibition improves abnormal coronary vasomotion and endothelial dysfunction in patients with atherosclerosis or its risk factors. BACKGROUND: Endothelial dysfunction, an early feature of atherosclerosis, contributes to abnormal vasomotion during stress. Angiotensin II may contribute to endothelial dysfunction in atherosclerosis. METHODS: In 25 patients, mean age 59±2 years, with atherosclerosis or its risk factors, we measured coronary vasomotion during flow-mediated dilation (FMD) in response to adenosine, cold pressor test (CPT) and exercise before and after AT1 receptor blockade with intracoronary losartan (5 mg). RESULTS: Losartan did not alter resting coronary vascular tone, but epicardial FMD improved from 5.6±1.5% to 8.9±1.8% (p=0.02). Abnormal epicardial vasomotion during CPT and exercise also improved with losartan from -1.7 ± 0.8% to 1.5 ± 0.1% (p=0.02) and -0.6±0.9% to 3.4±1.2% (p=0.009), respectively. Improvement in epicardial vasomotion was most prominent in segments with baseline endothelial dysfunction evidenced as constriction during stress. Microvascular dilation during adenosine, an endothelium-independent response, was unchanged with losartan. CONCLUSIONS: Inhibition of the coronary vascular AT1 receptors in patients with atherosclerosis improves epicardial vasomotion during stress, probably by improving endothelial dysfunction. Whether AT1 receptor blockade will provide long-term therapeutic benefits in atherosclerosis needs further investigation.

Original languageEnglish (US)
Pages (from-to)1089-1095
Number of pages7
JournalJournal of the American College of Cardiology
Volume38
Issue number4
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Angiotensin Type 1 Receptor
Atherosclerosis
Losartan
Dilatation
Exercise Test
Adenosine
Blood Vessels
Constriction
Angiotensin II
Endothelium

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis. / Prasad, Abhiram; Halcox, Julian P J; Waclawiw, Myron A.; Quyyumi, Arshed A.

In: Journal of the American College of Cardiology, Vol. 38, No. 4, 2001, p. 1089-1095.

Research output: Contribution to journalArticle

Prasad, Abhiram ; Halcox, Julian P J ; Waclawiw, Myron A. ; Quyyumi, Arshed A. / Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis. In: Journal of the American College of Cardiology. 2001 ; Vol. 38, No. 4. pp. 1089-1095.
@article{9ecd746822e9479c90210687edc1d0f1,
title = "Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis",
abstract = "OBJECTIVES: This study was performed to determine whether angiotensin type 1 (AT1) receptor inhibition improves abnormal coronary vasomotion and endothelial dysfunction in patients with atherosclerosis or its risk factors. BACKGROUND: Endothelial dysfunction, an early feature of atherosclerosis, contributes to abnormal vasomotion during stress. Angiotensin II may contribute to endothelial dysfunction in atherosclerosis. METHODS: In 25 patients, mean age 59±2 years, with atherosclerosis or its risk factors, we measured coronary vasomotion during flow-mediated dilation (FMD) in response to adenosine, cold pressor test (CPT) and exercise before and after AT1 receptor blockade with intracoronary losartan (5 mg). RESULTS: Losartan did not alter resting coronary vascular tone, but epicardial FMD improved from 5.6±1.5{\%} to 8.9±1.8{\%} (p=0.02). Abnormal epicardial vasomotion during CPT and exercise also improved with losartan from -1.7 ± 0.8{\%} to 1.5 ± 0.1{\%} (p=0.02) and -0.6±0.9{\%} to 3.4±1.2{\%} (p=0.009), respectively. Improvement in epicardial vasomotion was most prominent in segments with baseline endothelial dysfunction evidenced as constriction during stress. Microvascular dilation during adenosine, an endothelium-independent response, was unchanged with losartan. CONCLUSIONS: Inhibition of the coronary vascular AT1 receptors in patients with atherosclerosis improves epicardial vasomotion during stress, probably by improving endothelial dysfunction. Whether AT1 receptor blockade will provide long-term therapeutic benefits in atherosclerosis needs further investigation.",
author = "Abhiram Prasad and Halcox, {Julian P J} and Waclawiw, {Myron A.} and Quyyumi, {Arshed A.}",
year = "2001",
doi = "10.1016/S0735-1097(01)01511-X",
language = "English (US)",
volume = "38",
pages = "1089--1095",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis

AU - Prasad, Abhiram

AU - Halcox, Julian P J

AU - Waclawiw, Myron A.

AU - Quyyumi, Arshed A.

PY - 2001

Y1 - 2001

N2 - OBJECTIVES: This study was performed to determine whether angiotensin type 1 (AT1) receptor inhibition improves abnormal coronary vasomotion and endothelial dysfunction in patients with atherosclerosis or its risk factors. BACKGROUND: Endothelial dysfunction, an early feature of atherosclerosis, contributes to abnormal vasomotion during stress. Angiotensin II may contribute to endothelial dysfunction in atherosclerosis. METHODS: In 25 patients, mean age 59±2 years, with atherosclerosis or its risk factors, we measured coronary vasomotion during flow-mediated dilation (FMD) in response to adenosine, cold pressor test (CPT) and exercise before and after AT1 receptor blockade with intracoronary losartan (5 mg). RESULTS: Losartan did not alter resting coronary vascular tone, but epicardial FMD improved from 5.6±1.5% to 8.9±1.8% (p=0.02). Abnormal epicardial vasomotion during CPT and exercise also improved with losartan from -1.7 ± 0.8% to 1.5 ± 0.1% (p=0.02) and -0.6±0.9% to 3.4±1.2% (p=0.009), respectively. Improvement in epicardial vasomotion was most prominent in segments with baseline endothelial dysfunction evidenced as constriction during stress. Microvascular dilation during adenosine, an endothelium-independent response, was unchanged with losartan. CONCLUSIONS: Inhibition of the coronary vascular AT1 receptors in patients with atherosclerosis improves epicardial vasomotion during stress, probably by improving endothelial dysfunction. Whether AT1 receptor blockade will provide long-term therapeutic benefits in atherosclerosis needs further investigation.

AB - OBJECTIVES: This study was performed to determine whether angiotensin type 1 (AT1) receptor inhibition improves abnormal coronary vasomotion and endothelial dysfunction in patients with atherosclerosis or its risk factors. BACKGROUND: Endothelial dysfunction, an early feature of atherosclerosis, contributes to abnormal vasomotion during stress. Angiotensin II may contribute to endothelial dysfunction in atherosclerosis. METHODS: In 25 patients, mean age 59±2 years, with atherosclerosis or its risk factors, we measured coronary vasomotion during flow-mediated dilation (FMD) in response to adenosine, cold pressor test (CPT) and exercise before and after AT1 receptor blockade with intracoronary losartan (5 mg). RESULTS: Losartan did not alter resting coronary vascular tone, but epicardial FMD improved from 5.6±1.5% to 8.9±1.8% (p=0.02). Abnormal epicardial vasomotion during CPT and exercise also improved with losartan from -1.7 ± 0.8% to 1.5 ± 0.1% (p=0.02) and -0.6±0.9% to 3.4±1.2% (p=0.009), respectively. Improvement in epicardial vasomotion was most prominent in segments with baseline endothelial dysfunction evidenced as constriction during stress. Microvascular dilation during adenosine, an endothelium-independent response, was unchanged with losartan. CONCLUSIONS: Inhibition of the coronary vascular AT1 receptors in patients with atherosclerosis improves epicardial vasomotion during stress, probably by improving endothelial dysfunction. Whether AT1 receptor blockade will provide long-term therapeutic benefits in atherosclerosis needs further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0034806542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034806542&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(01)01511-X

DO - 10.1016/S0735-1097(01)01511-X

M3 - Article

C2 - 11583887

AN - SCOPUS:0034806542

VL - 38

SP - 1089

EP - 1095

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 4

ER -